Difference between revisions of "Team:Bielefeld-CeBiTec/Results/Selection/Cloning"

Line 8: Line 8:
  
 
<div class="container text">
 
<div class="container text">
For the creation of our constructs we did a lot of literature researches to find the optimal construction for the selection. At last we have decided to make a two-hybrid
+
For the construction of our BioBricks we did a lot of literature research to identify optimal templates for the selection system. Finally we decided to build a two-hybrid
 
transcriptional activation system based on the cooperation of the repressor protein cI from one of two different phages with the omega subunit of the DNA-mediated  
 
transcriptional activation system based on the cooperation of the repressor protein cI from one of two different phages with the omega subunit of the DNA-mediated  
RNA polymerase of <i>Escherichia coli</i>. These two proteins were separated on two plasmid backbones with different antibiotic resistances. For the first construction of  
+
RNA polymerase of <i>Escherichia coli</i>. These two proteins were encoded on seperate plasmid backbones with different antibiotic resistances. For the first construction of  
 
our system the backbones <a href="http://parts.igem.org/Part:pSB1C3">pSB1C3</a> and <a href="http://parts.igem.org/Part:pSB1K3">pSB1K3</a> were used. Our target was the  
 
our system the backbones <a href="http://parts.igem.org/Part:pSB1C3">pSB1C3</a> and <a href="http://parts.igem.org/Part:pSB1K3">pSB1K3</a> were used. Our target was the  
construction of fusion proteins which contain on the one hand the cI protein fused with our target protein on the pSB1K3 plasmid (<a href="http://parts.igem.org/Part:BBa_K2082225">BBa_K2082225</a>, part in pSB1C3) and on the other hand the RpoZ protein fused
+
construction of fusion proteins, which contained on the one hand the cI protein fused with our target protein encoded on the pSB1K3 plasmid (<a href="http://parts.igem.org/Part:BBa_K2082225">BBa_K2082225</a>, part in pSB1C3) and on the other hand the RpoZ protein fused
with our Evobody on the pSB1C3 plasmid (<a href="http://parts.igem.org/Part:BBa_K2082221">BBa_K2082221</a>). The schematic for the construction is illustrated in the figure (X). For a positive control the domain SH2 of the tyrosine kinase Abl1
+
with our <b>Evobody</b> encoded on the pSB1C3 plasmid (<a href="http://parts.igem.org/Part:BBa_K2082221">BBa_K2082221</a>). The concept of the construction is illustrated in the figure (X). As positive control the domain SH2 of the tyrosine kinase Abl1
 
as target and the monobody HA4 as binding protein are used. Also, the HA4 mutations Y87A (<a href="http://parts.igem.org/Part:BBa_K2082222">BBa_K2082222</a>), R38A(<a href="http://parts.igem.org/Part:BBa_K2082223">BBa_K2082223</a>) and the double mutation  
 
as target and the monobody HA4 as binding protein are used. Also, the HA4 mutations Y87A (<a href="http://parts.igem.org/Part:BBa_K2082222">BBa_K2082222</a>), R38A(<a href="http://parts.igem.org/Part:BBa_K2082223">BBa_K2082223</a>) and the double mutation  
R38A and E52A (<a href="http://parts.igem.org/Part:BBa_K2082224">BBa_K2082224</a>) were created. Why we exactly used these proteins as our control you can read in our description of the
+
R38A and E52A (<a href="http://parts.igem.org/Part:BBa_K2082224">BBa_K2082224</a>) were created. A detailed explanation about our decision for this
<a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Bacterial_Two-Hybrid_System#Controls">bacterial two-hybrid system</a>.
+
<a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/Project/Selection/Bacterial_Two-Hybrid_System#Controls">bacterial two-hybrid system</a> is availble in our project description.
 
<br>
 
<br>
 
<center><tr>
 
<center><tr>
Line 27: Line 27:
 
</tr></center>
 
</tr></center>
 
<br>
 
<br>
In consideration of the space between the both halves of our RpoZ-HA4 construct we designed a 30 base-pairs linker with an anti-cMyc binding site for easy detection of the expression of  
+
In consideration of the space between both halves of our RpoZ-HA4 construct we designed a 30 base-pairs linker with an anti-cMyc binding site for easy detection of the expression of  
the protein within the <i>E. coli</i> coli by means of a <a href="#WesternBlot">western blot assay</a> with a Myc antibody. For the cI-SH2 protein we designed constructs with different linker
+
the protein within the <i>E. coli</i> coli via <a href="#WesternBlot">western blot assay</a> with a cMyc antibody. For the cI-SH2 fusion protein we designed constructs with the alternative linkers
possibilities. The Biobricks are designed without a linker (<a href="http://parts.igem.org/Part:BBa_K2082205">BBa_K2082205</a>), with a short 9 base-pair linker  
+
possibilities. The BioBricks are designed without a linker (<a href="http://parts.igem.org/Part:BBa_K2082205">BBa_K2082205</a>), with a short nine base-pair linker  
 
(<a href="http://parts.igem.org/Part:BBa_K2082206">BBa_K2082206</a>) and the cMyc-linker for integrated expression control (<a href="http://parts.igem.org/Part:BBa_K2082207">
 
(<a href="http://parts.igem.org/Part:BBa_K2082206">BBa_K2082206</a>) and the cMyc-linker for integrated expression control (<a href="http://parts.igem.org/Part:BBa_K2082207">
 
BBa_K2082207</a>).  
 
BBa_K2082207</a>).  
 
<br>
 
<br>
The reporter of our system is based on a lacZ promoter expanded by the OR1 binding site for the cI repressor protein of the phage 434. To make the first studies of the transcriptional  
+
The reporter of our system is based on a <i>lacZ</i> promoter expanded by the OR1 binding site for the cI repressor protein of the phage 434. To make the first studies of the transcriptional  
activation we choose a RFP gene as the reporter (<a href="http://parts.igem.org/Part:BBa_K2082211">BBa_K2082211</a>). Better interaction should result in higher expression of RFP and a stronger red fluorescence in the <i>E. coli</i> cell. Later for  
+
activation we choose a RFP gene as the reporter (<a href="http://parts.igem.org/Part:BBa_K2082211">BBa_K2082211</a>). Stronger interaction should result in higher expression of RFP and a stronger red fluorescence in the <i>E. coli</i> cell. Later for  
 
our final system the RFP is replaced by a beta-lactamase gene to put on a selection pressure on our bacteria(<a href="http://parts.igem.org/Part:BBa_K2082238">BBa_K2082238</a>). To use the reporter in our two plasmid system, the whole part was at first
 
our final system the RFP is replaced by a beta-lactamase gene to put on a selection pressure on our bacteria(<a href="http://parts.igem.org/Part:BBa_K2082238">BBa_K2082238</a>). To use the reporter in our two plasmid system, the whole part was at first
integrated upstream of the SH2-cI fusion protein(<a href="http://parts.igem.org/Part:BBa_K2082231">BBa_K2082231</a>).   
+
integrated upstream of the SH2-cI fusion protein encoding sequence(<a href="http://parts.igem.org/Part:BBa_K2082231">BBa_K2082231</a>).   
 
<img align="right" src="https://static.igem.org/mediawiki/2016/e/eb/Bielefeld_CeBiTec_2016_10_18_SEL_SH2_reporter.png" width=500 heigth=1200>
 
<img align="right" src="https://static.igem.org/mediawiki/2016/e/eb/Bielefeld_CeBiTec_2016_10_18_SEL_SH2_reporter.png" width=500 heigth=1200>
 
<br>
 
<br>
Based on the problem, that the reporter activity could be dependent on the copy number of our plasmid we decided to made a knock-in  
+
The reporter activity could be dependent on the plasmid number. Therefore, a knock-in  
of the reporter in the genome of our final <i>E. coli</i> strain JS200 with the <a href="#CRISPR">CRISPR/Cas9</a> system. The main construct of the Knock-Out was also added to the part registry (<a href="http://parts.igem.org/Part:BBa_K2082251">BBa_K2082251</a>)
+
of the reporter in the genome of our final <i>E. coli</i> strain JS200 with the <a href="#CRISPR">CRISPR/Cas9</a> system was done. The main construct of the knock-out was also added to the part registry (<a href="http://parts.igem.org/Part:BBa_K2082251">BBa_K2082251</a>)
 
<br>
 
<br>
 
For different tests with our bacterial two-hybrid system more constructs were created. At first the DNA binding domain and the associated OR1 binding site was changed from the cI of the phage
 
For different tests with our bacterial two-hybrid system more constructs were created. At first the DNA binding domain and the associated OR1 binding site was changed from the cI of the phage
 
434 to the cI protein of the phage lambda(<a href="http://parts.igem.org/Part:BBa_K2082252">BBa_K2082252</a>). For the cI lambda sequence the part <a href="http://parts.igem.org/Part:BBa_K105004">BBa_K105004</a> and for the OR1 binding sequence the part <a href="http://parts.igem.org/Part:BBa_K105021">
 
434 to the cI protein of the phage lambda(<a href="http://parts.igem.org/Part:BBa_K2082252">BBa_K2082252</a>). For the cI lambda sequence the part <a href="http://parts.igem.org/Part:BBa_K105004">BBa_K105004</a> and for the OR1 binding sequence the part <a href="http://parts.igem.org/Part:BBa_K105021">
BBa_K105021</a> were used. Another created part was a addition of the OR2 binding site (Hartmann et al. 2003) to our construct <a href="http://parts.igem.org/Part:BBa_K2082239">BBa_K2082239</a> to analyze if two binding sites  
+
BBa_K105021</a> were used, respectivly. Another created part was an addition of the OR2 binding site (Hartmann et al. 2003) to our construct <a href="http://parts.igem.org/Part:BBa_K2082239">BBa_K2082239</a> to analyze if two binding sites  
 
would make the binding strength of our DNA binding domain better.  
 
would make the binding strength of our DNA binding domain better.  
 
<br>
 
<br>
In our project development we talked a lot with some <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/HP/Experts">experts</a>, who had many interesting ideas for our system. One of the ideas was a change of our  
+
The project development was supported by several <a href="https://2016.igem.org/Team:Bielefeld-CeBiTec/HP/Experts">experts</a>, who had many interesting advices for our system. One of the ideas was a change of our  
resistence gene from beta-lactamase to the more common used antibiotic tetracycline. Therefore, we designed a part, which contains a reporter with a tetracycline resistence gene <i>tetA</i> cloned upstream of the RFP gene(<a href="http://parts.igem.org/Part:BBa_K2082237">BBa_K2082237</a>).
+
resistance gene from beta-lactamase to the more commonly used antibiotic tetracycline. Therefore, we designed a part, which contains a reporter with a tetracycline resistance gene <i>tetA</i> cloned upstream of the RFP gene(<a href="http://parts.igem.org/Part:BBa_K2082237">BBa_K2082237</a>).
 
This created a possibility to make a quantitative and qualitative analysis of the functionality of the bacterial two-hybrid system.  
 
This created a possibility to make a quantitative and qualitative analysis of the functionality of the bacterial two-hybrid system.  
  
 
</div>
 
</div>

Revision as of 16:34, 19 October 2016



Assembly

For the construction of our BioBricks we did a lot of literature research to identify optimal templates for the selection system. Finally we decided to build a two-hybrid transcriptional activation system based on the cooperation of the repressor protein cI from one of two different phages with the omega subunit of the DNA-mediated RNA polymerase of Escherichia coli. These two proteins were encoded on seperate plasmid backbones with different antibiotic resistances. For the first construction of our system the backbones pSB1C3 and pSB1K3 were used. Our target was the construction of fusion proteins, which contained on the one hand the cI protein fused with our target protein encoded on the pSB1K3 plasmid (BBa_K2082225, part in pSB1C3) and on the other hand the RpoZ protein fused with our Evobody encoded on the pSB1C3 plasmid (BBa_K2082221). The concept of the construction is illustrated in the figure (X). As positive control the domain SH2 of the tyrosine kinase Abl1 as target and the monobody HA4 as binding protein are used. Also, the HA4 mutations Y87A (BBa_K2082222), R38A(BBa_K2082223) and the double mutation R38A and E52A (BBa_K2082224) were created. A detailed explanation about our decision for this bacterial two-hybrid system is availble in our project description.

In consideration of the space between both halves of our RpoZ-HA4 construct we designed a 30 base-pairs linker with an anti-cMyc binding site for easy detection of the expression of the protein within the E. coli coli via western blot assay with a cMyc antibody. For the cI-SH2 fusion protein we designed constructs with the alternative linkers possibilities. The BioBricks are designed without a linker (BBa_K2082205), with a short nine base-pair linker (BBa_K2082206) and the cMyc-linker for integrated expression control ( BBa_K2082207).
The reporter of our system is based on a lacZ promoter expanded by the OR1 binding site for the cI repressor protein of the phage 434. To make the first studies of the transcriptional activation we choose a RFP gene as the reporter (BBa_K2082211). Stronger interaction should result in higher expression of RFP and a stronger red fluorescence in the E. coli cell. Later for our final system the RFP is replaced by a beta-lactamase gene to put on a selection pressure on our bacteria(BBa_K2082238). To use the reporter in our two plasmid system, the whole part was at first integrated upstream of the SH2-cI fusion protein encoding sequence(BBa_K2082231).
The reporter activity could be dependent on the plasmid number. Therefore, a knock-in of the reporter in the genome of our final E. coli strain JS200 with the CRISPR/Cas9 system was done. The main construct of the knock-out was also added to the part registry (BBa_K2082251)
For different tests with our bacterial two-hybrid system more constructs were created. At first the DNA binding domain and the associated OR1 binding site was changed from the cI of the phage 434 to the cI protein of the phage lambda(BBa_K2082252). For the cI lambda sequence the part BBa_K105004 and for the OR1 binding sequence the part BBa_K105021 were used, respectivly. Another created part was an addition of the OR2 binding site (Hartmann et al. 2003) to our construct BBa_K2082239 to analyze if two binding sites would make the binding strength of our DNA binding domain better.
The project development was supported by several experts, who had many interesting advices for our system. One of the ideas was a change of our resistance gene from beta-lactamase to the more commonly used antibiotic tetracycline. Therefore, we designed a part, which contains a reporter with a tetracycline resistance gene tetA cloned upstream of the RFP gene(BBa_K2082237). This created a possibility to make a quantitative and qualitative analysis of the functionality of the bacterial two-hybrid system.